However, beneath this success lies a growing concern: the sustainability of this growth trajectory, particularly as ...

Jim Cramer in a recent program on CNBC commented on Merck & Co Inc. (NYSE:MRK) earnings results and said the pharma giant’s ...

Merck (NYSE:MRK) recently announced a third-quarter dividend affirmation of $0.81 per share, underscoring its commitment to returning value to shareholders. Over the past week, the company's stock ...

Merck beats Q1 2025 estimates despite Gardasil sales drop, driven by Vaxneuvance, Winrevair & Welireg. Click here to find out ...

Merck is in a tight spot, balancing blockbuster Keytruda’s looming 2028 patent cliff and rough seas in China’s market.

This downturn can be attributed to several factors: a lowered guidance for 2025 and growing concerns about the long-term ...

Merck’s MRK shares have lost 21.3% so far this year compared with a decrease of 4.5% for the industry. The stock has also ...

DURHAM, N.C.--(BUSINESS WIRE)--Merck (NYSE: MRK), known as MSD outside of the United States and Canada, announced today the opening of a new, $1 billion, 225,000-square-foot facility dedicated to ...

Merck advises against changing Gardasil's approved dosing regimen despite studies suggesting single-dose efficacy. Read more ...

Pfizer, on the other hand, with its improving growth prospects, rising estimates, cheaper valuation, and higher dividend ...

As has been the case for several quarters now, Merck KGaA’s life science business continues to serve as a weathervane for the broader biopharma industry. For the full year, Merck now expects ...

Six years after Merck bought out Peloton Therapeutics, the New Jersey drugmaker is not remaining stationary with the crown jewel of the deal. On Wednesday, the FDA approved a third indication for ...